Dynamic Healthcare M&A Database

Acquiring Party	Ranbaxy Laboratories Limited, a large India-based generic drug company.
Transferring Party	Terapia S.A., a Romania-based generic drug company.
Sector	Biopharmaceuticals
Date	March 29, 2006
Analysis Provides major step for expanding Ranbaxy's European operations, with a broad product portfolio and deep pipeline. Ranbaxy will provide Terapia with additional products to launch in the domestic market at very cost competitive levels, thereby lowering costs and delivering value to both consumers and the domestic healthcare budget. Deal value $324m (11.6x LTM EBITDA and 4.05x sales of $80m). Being Eastern European based, Terapia's EBITDA margins are 35%.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 1Q06